Rituximab-associated progressive multifocal leukoencephalopathy

Vnitr Lek. 2017 Winter;63(1):60-64.

Abstract

The definition "Progressive Multifocal Leukoencephalopathy" (PML) was first used in 1958 to describe a fatal demyelinating central nervous system (CNS) disease in patients with lymphoproliferative disorders. In 1971, the virus responsible for the disease was isolated and named John Cunningham virus (JCV). We present a rare case of a 62-year-old male with chronic lymphocytic leukemia and PML. In our work, we discuss the diagnostic and therapeutic challenges and offer suggestions for preventing PML development. The main learning points are: 1. Regularly check the level of immunoglobulins and the CD4+ : CD8+ T-cell ratio, intravenous administration of immunoglobulins should be considered when recording their reduction. 2. In checking the CD4+ : CD8+ T-cell ratio and verifying the impossibility of raising the level of immunoglobulins, we must weigh the possible benefits of continuing treatment with monoclonal antibody against the risks. 3. Physicians should maintain a high index of suspicion for the development of PML in patients under treatment with monoclonal antibodies, especially when there is a new development of neurological signs or symptoms.Key words: JC virus - progressive multifocal leukoencephalopathy - recommendation - rituximab.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Brain / diagnostic imaging*
  • Cyclophosphamide / administration & dosage
  • Humans
  • Immunocompromised Host / immunology
  • JC Virus
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukoencephalopathy, Progressive Multifocal / diagnosis*
  • Leukoencephalopathy, Progressive Multifocal / etiology
  • Leukoencephalopathy, Progressive Multifocal / immunology
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Prednisone / administration & dosage
  • Rituximab / adverse effects*
  • Vincristine / administration & dosage

Substances

  • Antineoplastic Agents
  • Rituximab
  • Vincristine
  • Cyclophosphamide
  • Prednisone